Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps

List view / Grid view

Stem Cells

 

Lonza logo with background
Lonza logo with background
news

Lonza awarded contract to generate clinical grade iPSCs by the NIH CRM

10 October 2012 | By

The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The production of clinical grade iPSCs is considered a critical component to realizing the therapeutic potential of pluripotent stem…

Lonza logo with background
Lonza logo with background
news

Lonza announces license agreement with iPS Academia Japan

2 August 2012 | By

Lonza has entered a worldwide, non-exclusive licensing agreement with iPS Academia Japan, Inc. for its induced pluripotent stem cell (iPSC) patent portfolio. By entering this agreement, Lonza demonstrates its commitment to the field of regenerative medicine and reinforces its belief that iPSCs are a key platform technology for the cell…

FIGURE 2 Outline of a strategy for testing drugs that perturb embryonic development. Undifferentiated hES cells are grown in (a) control conditions and (b) in the presence of a drug, and then assessed by a high content assay to determine the effect of a drug on cells (by examining the number of cells, expression of markers associated with the differentiated and undifferentiated state, colony number and size). Cells from both conditions are then induced to differentiate to specific cell types to assess the effect of drug treatment on the differentiation ability of hES cells. For example, low number of neurons upon drug treatment may indicate neurotoxic effects of the drug
FIGURE 2 Outline of a strategy for testing drugs that perturb embryonic development. Undifferentiated hES cells are grown in (a) control conditions and (b) in the presence of a drug, and then assessed by a high content assay to determine the effect of a drug on cells (by examining the number of cells, expression of markers associated with the differentiated and undifferentiated state, colony number and size). Cells from both conditions are then induced to differentiate to specific cell types to assess the effect of drug treatment on the differentiation ability of hES cells. For example, low number of neurons upon drug treatment may indicate neurotoxic effects of the drug
article

Drug screens on human stem cells: From understanding cell biology to predicting drug toxicity

19 October 2011 | By Ivana Barbaric and Peter W. Andrews, Centre for Stem Cell Biology, University of Sheffield

The Canadian physician William Osler said: “The person who takes medicine must recover twice, once from the disease and once from the medicine.” Indeed, all medicines have side effects – some of which may complicate a patient’s treatment, or in extreme cases may even be fatal. Of concern is the…

Figure 1. Engineering the Stem Cell Niche. The ability to assembly natural and manmade components into idealized biosynthetic 3D architectures requires a detailed understanding of the environment, along with the technology and expertise to manipulate them. This multiscale and multi-expertise approach is expected to lead to unprecedented breakthroughs in tissue engineering and biofabrication that benefit human health for an improved quality of life.
Figure 1. Engineering the Stem Cell Niche. The ability to assembly natural and manmade components into idealized biosynthetic 3D architectures requires a detailed understanding of the environment, along with the technology and expertise to manipulate them. This multiscale and multi-expertise approach is expected to lead to unprecedented breakthroughs in tissue engineering and biofabrication that benefit human health for an improved quality of life.
article

In search of the Holy Grail: Engineering the stem cell niche

19 April 2011 | By Janet L. Paluh, Associate Professor Nanobioscience, College of Nanoscale Science and Engineering, University at Albany SUNY and Guohao Dai and Douglas B. Chrisey, Biomedical Engineering, Rensselaer Polytechnic Institute

There is no other biomedical frontier that offers the stunning potential of human pluripotent stem cells and their progenitors in therapeutic applications to ease human suffering or in their ability to provide insights into development and diseases. Cell plasticity for reprogramming has revealed new opportunities in cell-based therapies and informed…

Figure 1
Figure 1
article

Turn back the clock and be healed Induced pluripotent stem cells and their future impact on drug discovery and regenerative medicine

9 May 2010 | By Paul D. Andrews, Drug Discovery Unit, College of Life Sciences, University of Dundee

They are only four years old and are getting everyone very excited; they were Science Magazine’s ‘Breakthrough of the Year 2008’ and Nature’s ‘Method of the Year 2009.’ Their discoverer, Shinya Yamanaka, shared the Lasker Award last year and is no doubt touted for a future Nobel Prize. ‘They’ are…

article

2009: A landmark year for stem cells

22 February 2010 | By

It would be fair to say that these past 12 months have been a watershed year for stem cell science. In years to come we may look back on 2009 and recognise it as the year in which nascent areas of science, medicine and technology came together to slowly nudge…

article

Combining perspectives: Multiscale integration of Stem Cell research

12 December 2009 | By

The promise of stem cell-based therapy is predicated on harnessing the plasticity of stem cell phenotypes to repair or replace damaged tissues. As technologies for detecting, isolating, modifying, and tracking stem cells improve, the very definition of what constitutes a stem cell is now an open question. Addressing this fundamental…